> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Octapharma’s Wilate Expanded Use in Adults/Adolescents
- URL: https://www.fdaweb.com/octapharmas-wilate-expanded-use-in-adults-adolescents/
- Published: 2019-10-09T12:00:00.000Z
- Updated: 2026-09-15T01:55:12.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145209

FDA has approved Octapharma’s Wilate (von Willebrand factor/coagulation factor VIII complex) for treating adults and adolescents with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes and on demand treatment and control of bleeding episodes. The human plasma-derived factor VIII was originally approved in 2009 for children and adults with von Willebrand Disease for on-demand treatment and control of bleeding episodes; and perioperative management of bleeding. The expanded approval was based on data from the “[Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02954575%3Fterm%3DNCT02954575%26rank%3D1&esheet=52108019&newsitemid=20191008005749&lan=en-US&anchor=Clinical+Study+to+Investigate+the+PK%2C+Efficacy%2C+and+Safety+of+Wilate+in+Patients+With+Severe+Hemophilia+A&index=5&md5=f715e65dce36fb72d15bfded11110825&ref=fdaweb.com),” (ClinicalTrials.gov Identifier: NCT02954575).